Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or Atypical antipsychotic

or Opioid

Use the filters below to narrow your results.

None (3) · Codeine (2)

None (13) · (multiple, generic dominant) (1) · Akineton (1) · Alfenta (1) · Apokyn (1) · Artane (1) · Azilect (1) · Caplyta (1) · Cogentin (1) · Comtan (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dostinex (1) · Duragesic (1) · Eldepryl (1) · Heroin (1) · Krokodil (1) · Neupro (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Ongentys (1) · Opana (1) · Parlodel (1) · Rexulti (1) · Sinemet (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Symmetrel (1) · Talwin (1) · Tasmar (1) · Ultiva (1) · Vicodin (1) · Vraylar (1) · Xadago (1)

None (2) · Active metabolite of tramadol; mu-opioid agonist (1) · Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Extremely potent mu-opioid receptor agonist (1) · Highly potent mu-opioid receptor agonist (1) · Irreversible selective MAO-B inhibitor (2) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; fentanyl analogue (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Opioid receptor partial agonist/antagonist; toxic alkaloid (1) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Peripheral COMT inhibitor (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (6) · Prodrug of morphine; mu-opioid receptor agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective M1 muscarinic antagonist (1) · Selective mu-opioid receptor agonist (1) · Ultra-short-acting mu-opioid agonist (1)

None (45) · Mild to moderate pain; cough suppression (low-dose). (1) · Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) · Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)

None (45) · 42 mg PO once daily with food (no titration) (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

None (45) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · 42 mg capsules (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (45) · 360 mg/day (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · 42 mg/d (1) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1)

None (45) · Oral (3) · PO (only formulation marketed in the US). (1)

None (45) · 30–60 min (PO) (1) · Antipsychotic effect over weeks (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · Weeks for psychosis/mood efficacy (1)

None (45) · 4–6 hours (1) · Daily dosing (2) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)

None (45) · 2.5–3 hours (1) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · ~18 hours (terminal) (1) · ~91 hours (1)

None (45) · Adequate oral bioavailability (1) · Limited but adequate; take with food (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~95% (1)

None (45) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data (1) · Limited data; National Pregnancy Registry available (1) · Limited data; National Pregnancy Registry for Atypical Antipsychotics (1)

None (45) · Rx (3) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)